A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age
Latest Information Update: 27 Apr 2023
At a glance
- Drugs ZF 2001 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Anhui Zhifei Longcom Biopharmaceutical
Most Recent Events
- 23 Apr 2023 Status changed from active, no longer recruiting to completed.
- 27 Sep 2022 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2021 New trial record